

Safe Harbor Statement

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally relate to future events or our future financial or operating performance. Forward-looking statements in this presentation include, but are not limited to, the following: Medicare broker industry trends, our estimates regarding Medicare enrollment growth; our estimates regarding commissions receivable collection; our estimates of constrained lifetime value of commissions per approved member; our 2024 operational priorities, including our business and growth strategy, local market strategy, branding, and member loyalty and retention strategy; our 2024 annual guidance for total revenue, GAAP net loss, adjusted EBITDA and operating cash flow; the expected impact of positive net adjustment revenue on our 2024 annual guidance; our operational initiatives, including our Agency and Amplify fulfillment models and new platform features, and the expected impact of these initiatives on our business and financial results; our investments in technology and operational initiatives and expected impact of these investments on our business; and other statements regarding our future operations, financial condition, prospects and business strategies. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include those set forth in our filings with the Securities and Exchange Commission, including our latest Form 10-Q and 10-K. The forward-looking statements in this presentation are based on information available to us as of today, and we disclaim any obligation to update any forward-looking statements, except as required by law.

Non-GAAP Information

This presentation includes both GAAP and non-GAAP financial measures. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for results prepared in accordance with GAAP. A reconciliation of the non-GAAP financial measures included in this presentation to the most directly comparable GAAP financial measures is available in the Appendix to this presentation. Management uses both GAAP and non-GAAP information in evaluating and operating its business internally and as such has determined that it is important to provide this information to investors.

Q1 2024 Earnings Highlights

eHealth delivered strong first quarter performance underpinned by revenue growth and growth in approved members. We are on track to reach our financial goals for FY 2024.

- Q1 2024 total revenue of \$93.0 million increased 26% compared to Q1 2023 total revenue of \$73.7 million.
- > Q1 2024 Medicare Advantage approved members increased 9% to 65,750 compared to Q1 2023 Medicare Advantage approved members of 60,451.
- > Q1 2024 GAAP net loss of \$17.0 million improved \$2.9 million year-over-year. Q1 2024 adjusted EBITDA⁽¹⁾ of \$(1.7) million improved \$11.0 million compared to \$(12.7) million in 01 2023.
- > Q1 2024 Medicare Advantage LTV increased 6% to \$952 from \$901 in Q1 2023, driven primarily by favorable carrier and contract mix.
- Operating cash flow for the trailing twelve months ended March 31, 2024, was \$3.3 million.

⁽¹⁾ Adjusted EBITDA is calculated by excluding dividends for preferred stock and change in preferred stock redemption value (together the "impact from preferred stock"), provision for (benefit from) income taxes, depreciation and amortization, stockbased compensation expense, amortization of intangible assets, impairment, restructuring and other charges, interest expense, other income (expense), net, and other non-recurring charges from GAAP net income (loss) attributable to common stockholders. Other non-recurring charges to GAAP net income (loss) attributable to common stockholders may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments and the cumulative effect of a change in accounting principles.

Medicare Broker Industry Trends


Old Model

Proliferation of distribution platforms, many unprofitable

Emphasis on volume production

Large marketing budgets deployed each AEP

Negative cash flow profile of Medicare Advantage distributors



New Model

Industry consolidation underway

Emphasis on profitability

Rationalization of marketing spend across all key channels


Focus on cash generation through diversification, alternative monetization models, etc.

eHealth was ahead of the curve as we launched our Business Transformation Plan in 2022 to enhance enrollment quality, rebuild marketing strategies, launch re-brand, and substantially improve cash flow profile of our business.


Q1 2024 Total Revenue Grew Year-over-Year with Improved Profitability

Enhanced profitability metrics reflect strong topline growth accompanied by fixed cost reductions.

Q1 2024 GAAP net loss includes onetime expenses including \$6.3 million of impairment and restructuring charges related to lease exits and other costreduction efforts.









⁽¹⁾ Adjusted EBITDA is calculated by excluding the impact from preferred stock, provision for (benefit from) income taxes, depreciation and amortization, stock-based compensation expense, amortization of intangible assets, impairment, restructuring and other charges, interest expense, other income (expense), net, and other non-recurring charges from GAAP net income (loss) attributable to common stockholders. Other non-recurring charges to GAAP net income (loss) attributable to common stockholders may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments and the cumulative effect of a change in accounting principles.


Q1 2024 Medicare Segment Performance


Q1 '24 Medicare approved members increased 10% YoY reflecting strong execution in both fulfillment models, core Agency and Amplify.

Q1 '24 Medicare noncommission revenue was \$11.6 million -YoY growth of more than 100%.









⁽¹⁾ Segment profit (loss) is calculated as total revenue for the applicable segment less direct and indirect allocated marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses, excluding stock-based compensation expense, depreciation and amortization, impairment, restructuring and other charges, interest expense and other income (expense), net.

Recently Launched New Features ePerks and Live Advise



- Launched in early Q2 2024
- Loyalty program that offers our members a seamless start to access their plan benefits and services, a plan check-up, and offers & discounts on partner services
- Since its April launch, we have already enrolled more than 200,000 existing eHealth Medicare customers
- Expected to impact retention and customer affinity

Live Advise



- Limited launch in early Q2 2024
- Offers secure one-way video chat capability
- Allows customers to see their benefit advisor during the enrollment process, fostering additional connection
- Expected to impact enrollment quality and sales efficiency

Cash Flow & Balance Sheet Highlights

Operating cash flow for Q1 '24 was \$70.8 million, relative to \$60.8 million in Q1 '23. Importantly, our operating cash flow for TTM ended 3/31/24 was positive \$3.3 million – up from negative \$13.2 million a year ago – and exceeded our goal of breakeven operating cash flow for this period. Our next milestone is free cash flow generation.







Total Cash Collected by Revenue Type (\$, MM)


Q1 2024 total cash collections of \$180.5 million grew 13% on a year-over-year basis, driven by an increase in non-commission revenue as well as increased commission payments generated by our existing book of business.



⁽¹⁾ We distinguish between commission and non-commission based cash collections using the same methodology we use to distinguish between commission revenue and revenue from non-commission sources, which can be found in our Annual Report on Form 10-K filed with the SEC on February 29, 2024.

Trailing 12-Month Profitability and Cash Flows

Following the implementation of our Business Transformation, we have seen steady improvement in profitability and cash flow performance on a TTM basis.



⁽¹⁾ Adjusted EBITDA is calculated by excluding the impact from preferred stock, provision for (benefit from) income taxes, depreciation and amortization, stock-based compensation expense, amortization of intangible assets, impairment, restructuring and other charges, interest expense, other income (expense), net, and other non-recurring charges from GAAP net income (loss) attributable to common stockholders may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments and the cumulative effect of a change in accounting principles.

⁽²⁾ Free cash flow is calculated as net cash provided by (used in) operating activities reduced by capitalized internal-use software and website development costs and purchases of property and equipment and other assets.

FY24 Operational Priorities

Grow revenue yearover-year while producing positive adjusted **EBITDA**

Advance our local market focused. omni-channel enrollment engine to drive higher conversions and greater margins

Launch the next phase of our member loyalty & retention strategy

Drive our B2B strategy and fortify the organizational foundation that supports our strategic partners and direct-toemployer opportunities

5

Enhance eHealth's comprehensive product portfolio **beyond Medicare Advantage agency** business to drive yearround growth

Two Distinct Fulfillment Models

- Both models capitalize on strong and growing Medicare Advantage market
- Can be expanded to other eHealth products

Agency (Choice)

eHealth Marketing Engine

National & Local **Market Advisors**

Online Marketplace

Proprietary Plan Recommendation Algorithm

Products: MA, MS, PDP, IFP, SMB, Ancillary

Amplify (Carrier Dedicated)

Carrier Demand Generation Efforts

Dedicated Benefit Advisors

Expert Match with Best Plan from that Carrier


Products: MA, MS, PDP

- Primarily a Broker of Record model
- LTV-based revenue
- Recurring cash commission payments
- Commissions receivable created
- Flows through reported approval/membership metrics
- Variable cost: marketing and agent

- Evolving from LTV-based in FY23 and Q1 '24 into primarily fee-based revenue model in Q2 (with some broker-of-record)
- Fee-based revenue
 - Upfront cash payment
 - No commissions receivable created
 - Does not impact enrollment or membership metrics
 - Variable cost: primarily agent (partially offset by carrier fees)

Amplify vs Agency Financial View

Q1 '24 Revenue Breakdown (\$, MM)



Amplify annual gross margin target of 30%-35% in line with our margin target for Medicare Agency

Expected FY 2024 Contribution as Amplify Scales and Transitions to BPO Model

eHealth Cash Profile Medicare Revenue Positive Positive Contributor Contributor **Medicare Volume Processed** Adj. EBITDA Positive Positive Contributor Contributor **Est. Medicare Membership Medicare Approved Members** Minimal Impact Minimal Impact

Q4 '23 & Q1 '24 Amplify Compensation Model: Majority Broker-of-Record



Q2 '24 & Beyond Amplify Compensation Model:

Largest contracts Fee-Based BPO


FY24 Guidance

We are reiterating our previously issued guidance ranges for FY 2024. Guidance includes an estimate for positive net adjustment revenue in the range of \$0 to \$15 million reflective of potential tail revenue that was previously constrained.

2024 Full Year Guidance	Range (in millions)
Total Revenue	\$450 – \$475
GAAP Net Income (Loss)	(\$40) – (\$20)
Adjusted EBITDA ⁽¹⁾	(\$5) – \$20
Operating Cash Flow	(\$15) – (\$5)

⁽¹⁾ Adjusted EBITDA is calculated by excluding the impact from preferred stock, provision for (benefit from) income taxes, depreciation and amortization, stock-based compensation expense, amortization of intangible assets, impairment, restructuring and other charges, interest expense, other income (expense), net, and other non-recurring charges from GAAP net income (loss) attributable to common stockholders. Other non-recurring charges to GAAP net income (loss) attributable to common stockholders may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments and the cumulative effect of a change in accounting principles.

Appendix



Reconciliation of GAAP to Non-GAAP Financial Measures

Reconciliation of GAAP Net Loss Attributable to Common Stockholders to Adjusted EBITDA (in thousands):

	Three months ended														
		mber 31, 2020	March 31, 2021	June 30, 2021	September 30, 2021	December 31, 2021	March 31, 2022	June 30, 2022	September 30, 2022	December 31, 2022	March 31, 2023	June 30, 2023	September 30, 2023	December 31, 2023	March 31, 2024
Net income (loss) attributable to common															
stockholders	\$	59,873	\$ (800)	\$ (22,888	3) \$ (59,948)	\$ (39,306)	\$ (39,960)	\$ (45,029)	\$ (46,998)	\$ 12,572	\$ (28,048)	\$ (32,915)	\$ (47,243)	\$ 41,691	\$ (27,711)
Preferred stock dividends		-	-	3,082	4,561	4,563	4,717	4,771	4,933	4,937	5,101	5,223	5,320	5,321	5,480
Change in preferred stock redemption value		-	-	1,397	7 2,373	2,591	2,501	2,756	2,916	3,162	3,069	4,191	4,898	5,178	5,247
GAAP net income (loss)		59,873	(800)	(18,409	(53,014)	(32,152)	(32,742)	(37,502)	(39,149)	20,671	(19,878)	(23,501)	(37,025)	52,190	(16,984)
Stock-based compensation expense		3,450	11,402	8,245	5,234	7,976	5,285	5,505	5,144	4,382	4,994	6,193	6,554	5,472	5,540
Depreciation and amortization		3,539	3,944	3,997	4,899	5,491	4,778	5,349	5,558	5,423	5,245	5,151	4,745	4,775	4,406
Amortization of intangible assets		286	176	119	121	120	-	-	-	0	-	-	-	-	-
Impairment, restructuring and other		-	2,431		573	48,218	4,823	1,369	4,498	8,926	-	-	-	-	6,313
Interest expense		215	210	21:	213	211	1,171	1,980	2,094	2,382	2,580	2,721	2,821	2,852	2,809
Other (income) expense, net		(157)	(360)	(383	3) (402)	(455)	(150)	(813)	(1,447)	(1,541)	(1,988)	(2,829)	(2,683)	(1,953)	(2,391)
Provision for (benefit from) income taxes		19,462	308	(6,752	2) (12,834)	(1,237)	(7,993)	(9,138)	(9,767)	9,231	(3,608)	(2,543)	(2,509)	6,279	(1,345)
Adjusted EBITDA	\$	86,668	\$ 17,311	\$ (12,972	2) \$ (55,210)	\$ 28,172	\$ (24,828)	\$ (33,250)	\$ (33,069)	\$ 49,474	\$ (12,655)	\$ (14,808)	\$ (28,097)	\$ 69,615	\$ (1,652)
Trailing Twelve Month Adjusted EBITDA					\$ 35,797	\$ (22,699)	\$ (64,838)	\$ (85,116)	\$ (62,975)	\$ (41,673)	\$ (29,500)	\$ (11,058)	\$ (6,086)	\$ 14,055	\$ 25,058

Reconciliation of Net Cash Provided by (Used In) Operating Activities to Free Cash Flow (in thousands):

										Three	mon	nths ended										
	Dec	ember 31,	March 31	,	June 30,	September 3	0, D	ecember 31,	March 31,	June 30,	Sep	otember 30,	December	31,	March 31,	June 3	30,	Septen	nber 30,	Decemb	er 31,	March 31,
		2020	2021		2021	2021		2021	2022	2022		2022	2022		2023	202	3	20)23	202	3	2024
Net cash provided by (used in) operating																						
activities	\$	(96,901)	\$ 42,80	9 \$	(32,083)	\$ (71,04	47) \$	(102,301)	\$ 47,112	\$ (25,766)	\$	(29,636)	\$ (18,5	79) \$	60,803	\$ (9,428)	\$	(24,681)	\$ (3	3,386)	\$ 70,761
Capitalized internal-use software and																						
website development costs		(3,923)	(3,24	2)	(4,100)	(5,24	17)	(4,403)	(4,205)	(4,171)		(4,164)	(2,	752)	(2,164)	(2,038)		(2,826)	(:	L,665)	(2,286)
Purchases of property and equipment and																						
other assets		(1,297)	(1,89	9)	(806)	(84	19)	(311)	(55)	(172)		35		(22)	(67)		(306)		(1,386)		(327)	(204)
Free Cash Flow	\$	(102,121)	\$ 37,66	8 \$	(36,989)	\$ (77,14	43) \$	(107,015)	\$ 42,852	\$ (30,109)	\$	(33,765)	\$ (21,	53) \$	58,572	\$ (1	1,772)	\$	(28,893)	\$ (3	5,378)	\$ 68,271
Trailing Twelve Month Free Cash Flow						\$ (178,58	35) \$	(183,479)	\$(178,295)	\$(171,415)	\$	(128,037)	\$ (42,	75) \$	(26,655)	\$ (8,318)	\$	(3,446)	\$ (1	7,471)	\$ (7,772)

Guidance GAAP Net Loss Attributable to Common Stockholders to Adjusted EBITDA

(in millions)

	Full Year 2024 Guidance					
		Low	High			
GAAP net loss attributable to common stockholders	\$	(85.0) \$	(65.0)			
Impact from preferred stock		45.0	45.0			
GAAP net loss		(40.0)	(20.0)			
Stock-based compensation expense		20.0	17.0			
Depreciation and amortization		19.0	18.0			
Impairment, restructuring and other charges		1.0	1.0			
Interest expense		11.0	10.0			
Other income, net		(8.0)	(9.0)			
Provision for (benefit from) income taxes		(8.0)	3.0			
Adjusted EBITDA	\$	(5.0) \$	20.0			